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Intratubular germ cell neoplasia, the precursor of testicular germ cell tumors (TGCTs), is hypothesized to arise
during embryogenesis from developmentally arrested primordial germ cells (PGCs) or gonocytes. In early
embryonal life, the PGCs migrate from the yolk sac to the dorsal body wall where the cell population separates
before colonizing the genital ridges. However, whether the malignant transformation takes place before or after
this separation is controversial. We have explored the somatic exome-wide mutational spectra of bilateral TGCT to
provide novel insight into the in utero critical time frame of malignant transformation and TGCT pathogenesis.
Exome sequencing was performed in five patients with bilateral TGCT (eight tumors), of these three patients in
whom both tumors were available (six tumors) and two patients each with only one available tumor (two tumors).
Selected loci were explored by Sanger sequencing in 71 patients with bilateral TGCT. From the exome-wide
mutational spectra, no identical mutations in any of the three bilateral tumor pairs were identified. Exome
sequencing of all eight tumors revealed 87 somatic non-synonymous mutations (median 10 per tumor; range 5-
21), some in already known cancer genes such as CIITA, NEB, platelet-derived growth factor receptor α (PDGFRA),
and WHSC1. SUPT6H was found recurrently mutated in two tumors. We suggest independent development
lineages of bilateral TGCT. Thus, malignant transformation into intratubular germ cell neoplasia is likely to occur
after the migration of PGCs. We reveal possible drivers of TGCT pathogenesis, such as mutated PDGFRA,
potentially with therapeutic implications for TGCT patients.
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The incidence of testicular germ cell tumors (TGCTs) has increased
considerably during the last 50 years and is currently the most
frequent malignancy in men aged 15 to 44 years in the Western
developed world [1]. TGCTs evolve from the precursor intratubular
germ cell neoplasia unspecified (also known as carcinoma in situ),
which is hypothesized to originate in utero from developmentally
arrested primordial germ cells (PGCs) or gonocytes (GCs) [2]. In
early embryonal life, PGCs migrate from the yolk sac to the dorsal
body wall where the cell population separates before colonizing the
genital ridges, the precursors of the gonads [3]. However, it is
unsettled whether malignant transformation occurs before or after
this separation.
To our knowledge, whole-genome or exome sequencing data from
TGCT has never been reported [4–6]. Besides some reports on KIT
mutations in both bilateral and unilateral TGCTs [7–10], the
knowledge on gene mutations in TGCT as such is sparse [11]. In a
recent exome sequencing study of intracranial germ cell tumors,
mutations involving the KIT/RAS signaling pathway were found in
more than 50% of the cases [12]. A monoclonal origin of bilateral
TGCT has been proposed based on the identification of substantial
concordance of selected KIT mutations among pairs of bilateral
TGCTs [10]. Nevertheless, these are data from only one single gene
that also frequently carries identical mutations in tumors from
different patients. As such, variants in a mutational hotspot in KIT
will not prove monoclonality of bilateral TGCT. Principally, many
molecular characteristics can be used to explore the clonality of
bilateral TGCT, including genetic and epigenetic changes and
expression of miRNA, mRNA, and proteins. Among these, changes
in the DNA sequence are likely to be the most stable and as such
suitable for clonality analyses.
Here, we report an exome-wide approach to explore the putative
concordance in somatic mutations between bilateral TGCTs,
revealing their monoclonal or polyclonal origin. We hypothesize
that the occurrence of malignant transformation and associated
somatic mutations in PGCs at a pre-separation stage would reflect in
identical somatic mutations in subsequent bilateral TGCTs. By
comparing the somatic exome-wide mutational spectra of bilateral
tumor pairs, we were able to reveal their mutual diversity, opposing
the notion of a monoclonal origin. Furthermore, as this is the first
exome sequencing analysis of TGCT, we also provide new insights
into the general mutational spectra of this malignancy.
Materials and Methods
Patients and Tissue Samples
Seventy-six patients diagnosed with germ cell cancer during 1969
to 2011 and who fulfilled the inclusion criteria of bilateral TGCT or
extragonadal germ cell tumor (EGCT) in combination with TGCT
were recruited from The Norwegian Radium Hospital, Oslo
University Hospital registry. Only patients with available fresh frozen
or formalin-fixed paraffin-embedded (FFPE) samples from tumor and
normal tissues were eligible. The study was approved by Regional
Committee for Medical and Health Research Ethics South-East D
(2011/1588). All patients eligible for exome sequencing and alive at
the time of study inclusion signed an informed consent formula.
All fresh frozen and most of the FFPE tissue samples were available
from established study or diagnostic biobanks at The Norwegian
Radium Hospital, Oslo University Hospital. The remaining FFPEtissue samples were obtained from 13 different diagnostic tissue
biobanks in Norway. Fresh frozen and FFPE tumor tissue samples
were obtained from radical/partial orchiectomy, open surgical biopsy,
or retroperitoneal/mediastinal/supraclavicular surgery. Fresh frozen
and FFPE normal samples were obtained from blood/fibroblasts
(exome sequencing series) and spermatic cord (extended series),
respectively. Sections from all samples (exome sequencing and
extended series) were stained with hematoxylin and eosin and
evaluated by an experienced uropathologist. Hematoxylin and eosin–
stained sections from all normal tissue samples in the extended series
were reevaluated to ensure absence of spermatic cord tumor
infiltration. All matched tumor-normal pairs in the exome series
were genotyped with the AmpFLSTR Identifiler PCR Amplification
Kit (Applied Biosystems by Life Technologies, Thermo Fisher
Scientific, Waltham, MA) to confirm that each pair was obtained
from the same individual.
Nucleic Acid Isolation
The phenol/chloroform extraction method was applied to isolate
DNA from all fresh frozen samples (exome sequencing series) [13],
except for tumor II of patient 1, where the QIAamp DNA Mini Kit
was used (Qiagen, Hilden, Germany). DNA from FFPE samples
(extended series) was obtained from 4 × 25 μm tissue sections
collected from each selected FFPE block and was isolated using
QIAamp DNA Mini Kit (Qiagen) according to the manufacturer's
protocol except from an initial deparaffinization step. The extracted
DNA was eluted in a 200-μl volume and the DNA concentration was
quantified on a NanoDrop ND-1000 spectrophotometer (Thermo
Fisher Scientific).
Exome Sequencing
Genomic DNA from eight tumors and five normal samples were
analyzed by exome sequencing. DNA libraries (1050 ng input) were
constructed according to the manufacturer's instructions in the
Illumina TruSeq DNA Sample Preparation Guide, Rev. C (Illumina,
San Diego, CA). Libraries were enriched according to the TruSeq
Enrichment Guide, Rev. J (Illumina) to create exome captured
libraries. Cluster generation was carried out by the TruSeq PE Cluster
Kit v2 (Illumina) and the templates were multiplexed on Illumina
Genome Analyzer IIx flow cells. All samples were sequenced twice in
two independent runs on the Illumina Genome Analyzer IIx platform
with the TruSeq SBS Kit v5 (Illumina) and the sequence data were
merged to increase the total coverage.
Polymerase Chain Reaction and Sanger Sequencing
Selected loci were amplified by polymerase chain reaction (PCR)
and sequenced by Sanger sequencing. DNA from tumor and normal
tissues was amplified in a 10-μl reaction volume containing 10× PCR
buffer with 15 mM MgCl2 (Qiagen), dNTP mix, HotStarTaq DNA
Polymerase (Qiagen), and oligonucleotide primers (Eurogentec,
Seraing, Belgium). Primer-specific annealing temperatures were
used for PCR amplification (Supplementary Table S1); 100 ng of
DNA from FFPE samples and 50 ng of DNA from fresh frozen
samples were amplified 40 and 30 cycles, respectively, before
purification of PCR products by adding 3 μl of ExoProStar 1-step
(GE Healthcare, Little Chalfont, United Kingdom) to each sample.
The subsequent sequence reaction was carried out using the BigDye
Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems by Life
Technologies, Thermo Fisher Scientific) before purification of
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(Applied Biosystems by Life Technologies, Thermo Fisher Scientific).
Capillary electrophoresis was performed on an ABI 3730 DNA
Analyzer (Applied Biosystems by Life Technologies, Thermo Fisher
Scientific). The electropherograms were visualized using the
Sequencing Analysis Software v5.3.1 (Applied Biosystems by Life
Technologies, Thermo Fisher Scientific) and scoring of sequences was
interpreted independently by two qualified persons. All identified
mutations were proven as somatic and confirmed by unidirectional
sequencing (forward or reverse primers) in two independent rounds of
PCR amplification.
Data Analysis
Paired-end sequencing reads of length 100 bp were aligned to the
reference genome GRCh37 with the Burrows-Wheeler Aligner,
version 0.6.2 [14]. Alignments were converted from sequence
alignment map files to the binary alignment map (BAM) format
with Picard, version 1.61 [15] and subsequently sorted and indexed
using SAMtools, version 0.1.18 [16]. The Picard toolbox was applied
to remove duplicates (MarkDuplicates) and for adding read group
information (AddOrReplaceReadGroups) to the BAM headers.
Genotype calling was carried out using the HaplotypeCaller tool
from the Genome Analysis Toolkit (GATK), version 2.3-9 [17,18].
Local realignment around insertions and deletions (indels) was
performed using the software tools RealignerTargetCreator and
IndelRealigner from GATK, while mate-pair information was
synchronized using the FixMateInformation tool from Picard. Base
quality scores were recalibrated by the BaseRecalibrator tool from
GATK. Output BAM files were sorted and indexed by Picard. To
detect candidate somatic mutations, and to filter out germline single
nucleotide variants and indels, tumor and matching normal samples
were compared, analyzing single nucleotide variants by MuTect,
version 1.1.4 [19] and indels by the SomaticIndelDetector tool from
the GATK package. Only exonic and intragenic candidate mutationsTable 1. Patients' Demographics and the Identified Genes with Somatic Non-Synonymous Mutation
Patient
ID
Tumor
ID
Age at Diagnosis
of TGCT
(Years)
Histology Amount of
Tumor Tissue
in Samples (%)
Number
of SBS
Number of
Non-Synonymous
SBS
Num
of I
1 I 31 Sem * 85 37 5 0
II 33 Sem * 90 42 11 1
2 † I 30 Sem * NA 24 7 9
II 40 Sem * NA 53 20 2
3 II 38 Nsem ‡ 50 37 9 1
4 § I 30 Sem * 80 ¶ 26 5 0
II 30 Nsem ‡ 40 31 5 3
5 II 26 Nsem ‡ 30 47 16 0
Abbreviations: Sem, seminoma; NSem, non-seminoma; NA, not available.
* Pure seminoma.
† Familial aggregation of TGCT.
‡ Non-seminoma independent of seminoma components.
§ Bilateral synchronous TGCT.
¶ 50% lymphocytes in tumor tissue.within a range of 100 bp from nearest exon were nominated for
further analysis. GATK bundle files representing dbSNP (version
138) and other known sites reported from the 1000 Genomes project
were used to filter out previously known variants [20]. Indels in repeat
regions that are likely to be introduced by sequencing errors were
filtered out of the call set. ANNOVAR, version 2013-02-21, was used
to appropriately annotate candidate variants [21]. Only mutations
with no (zero) variant reads in normal tissue were accepted. The
default coverage sufficiency threshold in the MuTect algorithm (≥14
and ≥8 reads in tumor and normal samples, respectively) was applied
to dichotomize the discovered mutations (Supplementary Tables S2A
and S2B). Functional impact of selected mutations was evaluated in
silico by Mutation Assessor [22].
Results
A total of 76 patients with bilateral TGCT or EGCT and TGCT was
included in the present study. Exome sequencing of tumor and normal
samples was performed in five patients with bilateral TGCT. In three of
these patients, both tumors were available (six tumor samples), whereas
only one tumor was available in each of the remaining two patients (two
tumor samples). In total, exome sequencing was performed in 13
samples (eight tumor and five normal samples; Table 1). Targeted
analyses of selectedmutated genes were carried out in an extended series
of 71 patients by direct Sanger sequencing (Table 2).
Between 9.1 and 73.8 million sequence reads were generated for
each deep-sequenced sample, yielding a median coverage of 30.9
(range 4.6-48.9). Exome sequencing of tumor specimens revealed
297 somatic single-base substitutions (SBSs) and 16 somatic indels
(Supplementary Tables S2A and S2B). The median number of SBS
and indels were 37 (range 24-53) and 1 (range 0-9), respectively.
Among the overall 313 mutations, 78 were non-synonymous SBS
(median 8, range 5-20) and 9 were non-synonymous indels (median
0, range 0-7; Table 1). The median frequency of somatic non-
synonymous mutations (SBS + indels) per tumor reached merely 10s for the TGCT Series Analyzed by Exome Sequencing
ber
ndels
Number of
Non-Synonymous
Indels
Total Number of
Non-Synonymous
Mutations
Non-Synonymously Mutated Genes
0 5 ANK2, ANKRD36, CD40LG, PTPRA, ZNF569
0 11 BMP1, CSPG5, CIITA, GPN1, LEF1, LZTS2,
MAP1LC3C, NOL6, PDE10A, TNR, TUBGCP6
7 14 DNAAF1, JMY, LIPA, PCDHB9, PDXDC1,
PKD1L3, POLR2B, SRD5A3, TBC1D16,
TCF25, VSIG1, WDR66, ZNF253, ZNF43,
1 21 ABCC1, ARFGEF2, BIRC6, CCT2, MED10,
NEB, PBX4, PDGFRA, PDGFRA, PTMA,
PVRL3, RANBP9, RGS6, SUPT6H, TMEM87B,
TSEN2, TTN, TYR,USP34, WHSC1, ZCCHC11
0 9 CDC27, CDC27, FAM120A, FAM135B,
FILIP1, GOLGB1, NOS3, PHF19, XIRP2
0 5 ATG2B, MYO5A, OR10A4, WDR91, ZNF157
1 6 CACNA1B,MDN1, REV1, SCAND3, UNG, XAF1
0 16 BSDC1, BUD13, CETP, COPRS, DCHS1,
DNAJC28, KIDINS220, KL, NOL8,
OSBPL5, PCDH10, PTMA, SEC23B,
SUPT6H, TMEM237, UBR5
Table 2. PatientDemographics from the Extended TGCTSeries Analyzed byDirect Sanger Sequencing
Total number of patients included 71
Bilateral metachronous * TGCT 57
Bilateral synchronous † TGCT 11
EGCT and unilateral TGCT 2
EGCT and bilateral synchronous † TGCT 1
Site of tumors included (number of tumors)
TGCT 140
EGCT 3
Histology of tumors (number of tumors)
Sem ‡ 91
Nsem § 52
Age at diagnosis of first germ cell tumor (years)
Total: median (range) 29 (18-54)
Sem: median (range) 31 (22-54)
Nsem: median (range) 26 (18-47)
Time between first and second germ cell tumor (months)
Median (range) 57 (0-263)
Percentage of tumor tissue in samples
Median (range) 75 (5-100)
Number of samples with b20% tumor tissue 14
Abbreviations: Sem, seminoma; NSem, non-seminoma.
* N2 months before subsequent TGCT.
† ≤2 months before subsequent TGCT.
‡ Pure seminoma.
§ Non-seminoma independent of seminoma components.
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sequenced tumor samples are presented in Figure 1.
Both tumors were available for three of the five bilateral TGCT
patients included for exome sequencing, i.e., six of the eight tumor
samples were from three patients. Clonality of bilateral TGCT was
evaluated by comparing the mutational patterns of the matched
tumors in each of the three tumor pairs. From a total of 228 somatic
mutations identified in these six tumors, no identical SBSs or indels in
any of the tumor pairs were identified. However, patient 1 displayed
an identical non-synonymous mutation in the two tumors in
LSM14A with a number of alternative/reference reads of 3/36 and
3/37. However, as the number of alternative/reference reads in the
matching normal sample was 1/34, the mutations in LSM14A were
probably germline variants not previously filtered out.
By comparing the somatic non-synonymously mutated genes with
already known cancer genes [5,23,24], match was evident for CIITA,
NEB, PDGFRA and WHSC1. All the specific mutational variants we
identified in these genes were novel, except from WHSC1, in which0.00
0.25
0.50
0.75
1.00
Patient 1
Tumor I
Patient 1
Tumor II
Patient 2
Tumor I
Patient 2
Tumor II
Patient 3
Tumor II
P
T
Figure 1. The relative proportion of base substitution mutations of e
proportion of base substitution mutations across all tumors.an identical mutation has been identified in one sample of colorectal
cancer [25]. None of the somatic non-synonymous mutations were in
genes previously found associated with increased risk of TGCT,
according to genome-wide association studies [26–28].
In tumor II of patient 2, two somatic non-synonymous mutations in
PDGFRA appeared at exons 21 and 22 (Table 1 and Figure 2). These
mutations were confirmed by direct Sanger sequencing and further
evaluated in the extended tumor series in which 112 and 138 of 143
tumors were evaluable for the mutation analysis of exons 21 and 22,
respectively. However, neither identical mutations nor mutations
elsewhere in the PCR-amplified fragments were found among the
tumors in this series. Two somatic non-synonymous mutations in
CDC27 were identified in tumor II of patient 3. The combination of a
somatic non-synonymous mutation in PTMA and in SUPT6H was
identified in both tumor II of patient 2 and in tumor II of patient 5.We
performed direct Sanger sequencing of these gene loci and successfully
validated the two mutations in SUPT6H but not those in CDC27 and
PTMA. All recurrentlymutated genes are listed in Supplementary Table
S3. According to an in silico functional evaluation by the software
Mutation Assessor [22], the mutations in PDGFRA and SUPT6H were
suggested to have low and medium impact, respectively. Of note, eight
of the nine somatic non-synonymous indels were identified in the
tumors of patient 2.
No mutations in KIT were identified in the tumors analyzed by
exome sequencing. However, in the extended series, direct Sanger
sequencing revealed mutations in KIT exons 11 and 17 in 2 of 86
(2%) and 9 of 89 (10%) evaluable seminomas, respectively (Table 3).
None of these mutations were observed in both tumors among
matched pairs. In non-seminoma TCGT, we could not find
mutations in KIT in 50 and 52 of 52 tumors evaluable for analyses
of exons 11 and 17, respectively.
Discussion
The present exome-wide, discovery-driven approach comparing all
protein-coding sequences in three matched pairs of bilateral TGCT
provides robust data to suggest separate development of the two tumors
(Figure 3). The fact that no identical somatic mutations were uncovered
in any pairs of bilateral TGCT challenge the notion of a common
precancerous cell from which progeny cells migrate to both gonads in
early embryonal life. However, the hypothesis cannot be entirely
rejected, both because of the limited number of tumor pairs included inBase substitutions
C−>T G−>A
C−>G G−>C
C−>A G−>T
A−>T T−>A
A−>G T−>C
A−>C T−>G
atient 4
umor I
Patient 4
Tumor II
Patient 5
Tumor II Average
1
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Figure 2. The two somatic non-synonymous mutations in exons 21 and 22 of PDGFRA validated by direct Sanger sequencing and
their spatial relationship to KIT on chromosome band 4q12. The single base substitutions, both replacing guanine by cytosine, are
marked by blue arrows. The chromosomal location of KIT is included to demonstrate that PDGFRA is located adjacently upstream to KIT.
Genital ridges
Migrating PGCs
Malignant germ cells
Yolk sac
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Given that driver mutations, critical for tumorigenesis, occur before
PGC separation, we expected to find at least some identical mutations
in the tumor pairs. The possibility of mutations occurring in two
different PGCs before separation and the migration of these two cells to
different genital ridges cannot be excluded. However, we find this
unlikely as PGCs may increase their number by 500-fold during
migration [29]. On arrival at the genital ridges, the PGCs are renamed
GCs, which are still sexually indifferent and susceptible to alterations in
their tightly controlled microenvironment [2]. As separation and lateral
migration toward the genital ridges is seen from gestational weeks 5 to 6
[30], we suggest that PGCs/GCs transform into intratubular germ cell
neoplasia unspecified after this point of time.
In two reports, identicalKITmutations (all in exon 17, codon 816 or
823) were revealed in both testicles in 13/15 and 3/8 evaluable pairs of
bilateral TGCT, suggesting that the mutations had occurred in PGCsTable 3. Mutations in KIT Identified from the Extended TGCT Series Analyzed by Direct
Sanger Sequencing
Sample ID Exon Position Amino Acid Change
21 TC2 * 11 1727 TNC L576P
38 TC1 * 11 1727 TNC L576P
14 TC2 * 17 2446 GNC D816H
57 TC1 † 17 2447 ANC D816A
13 TC2 * 17 2447 ANT D816V
15 TC2 * 17 2447 ANT D816V
28 TC1 * 17 2447 ANT D816V
39 EGCT ‡ 17 2447 ANT D816V
66 TC2 * 17 2447 ANT D816V
25 TC1 † 17 2466 TNG N822K
87 TC1 † 17 2466 TNG N822K
Abbreviation: TC1/TC2, first/second tumor of a bilateral TGCT pair.
* Patient with bilateral metachronous TGCT (N2 months before subsequent TGCT).
† Patient with bilateral synchronous TGCT (≤2 months before subsequent TGCT).
‡ Patient with EGCT and unilateral TGCT.
Figure 3. In utero migration and separation of PGCs. According to
this embryogenesis model, the absence of identical somatic
mutations in matched pairs of bilateral TGCTs supports separate
clonal development and initiation of tumorigenesis after the PGC
population has migrated and separated into the gonadal ridges.
172 Exome Sequencing of Bilateral TGCTs Brabrand et al. Neoplasia Vol. 17, No. 2, 2015before their arrival at the genital ridges [7,10]. Consequently, the
hypothesis of a monoclonal origin of bilateral TGCT was proposed
[10]. However, as mutations inKIT exons 11 and 17 are found in about
10% to 40% of testicular seminomas [7–9,31–35], primarily in codon
816 of exon 17, several of the reported KITmutations among matched
pairs of bilateral TGCT may have occurred by coincidence.
Furthermore, as the high mutational frequencies of KIT in bilateral
TGCTs in these two reports are not verified in other studies, the results
should be interpreted with caution [8,9,33,36].
There is an ongoing debate whether somatic mutations of KIT in
TGCT predict the risk of contralateral disease [7–10,36]. We hereby
present mutational data of KIT from the largest number of bilateral
TGCTs hitherto reported, finding that the mutational frequency
among bilateral seminomas in our study is in line with the previously
reported frequency among unilateral seminomas [7–9,31–35]. Thus,
our data imply that mutations in KIT are inapt as predictors for
development of bilateral TGCT.
This is the first study presenting exome sequencing data from
TGCT, reporting 87 somatic non-synonymous mutations potentially
linked to TGCT development. To our knowledge, these mutations
have not formerly been identified in TGCT [25]. In a comprehensivePa
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other pediatric and adult solid tumors. Horizontal bars represent the
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et al. [5], and the actual numbers behind the visualization are summari
B-cell lymphoma; HCC, hepatocellular carcinoma; MSI, microsatellite
carcinoma; SCLC, small cell lung carcinoma.TGCT Sanger sequencing study, analyzing point mutations in
protein kinases, a remarkably low frequency of mutations was
identified [11]. From exome sequencing of intracranial germ cell
tumors, occurring typically near the time of puberty, a mean of nearly
six non-synonymous mutations per tumor has been found [12].
According to a recent review of genome-wide sequencing studies,
presenting the number of somatic non-synonymous mutations per
tumor across various cancer types (coverage depth: median 88.5,
range 20-304, 22/27 data sets with available data), our data establish
TGCT as the adult solid tumor with the lowest number of base level
mutations (Figure 4 and Supplementary Table S4) [5]. In fact, the
number of somatic non-synonymous mutations in TGCT is more
similar to pediatric than adult cancers. In the above data sets and in
our study, the downstream analysis pipelines were highly overlapping,
whereas estimation and reporting of the average sequence coverage,
optimally performed across all targeted regions, were not always as
conservative as in our study. In tumors of self-renewing tissues, the
cumulative number of cell renewals, and to some extent the patient’s
age, is associated with the amount of somatic mutations [37].
Although adult male germ cells are indeed highly proliferating, they
reside in an arrested, pre-meiotic state until puberty [38]. Therefore,0
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shorter period of cumulative germ cell renewals than reflected by the
chronological age may explain the correspondingly low mutational
frequency among TGCT and pediatric cancers.
Surprisingly, the relative proportion of C→A/G→T and C→T/
G→A base substitutions in TGCT appears higher and lower,
respectively, compared to most other cancer types included in the
TCGA pan-cancer analysis [39]. The significance of this finding
remains to be settled.
Tumor II of patient 2 had two novel somatic non-synonymous
SBS in PDGFRA, encoding the platelet-derived growth factor
receptor α. PDGFRA have indeed been found overexpressed in
TGCT and a functional impact of PDGFRA signaling in TGCT
angiogenesis and growth has been indicated [40–42]. Thus, activating
somatic mutations in PDGFRA could represent potential molecular
targets in treatment of TGCT patients with metastatic disease
refractory to cisplatin-based chemotherapy. Interestingly, PDGFRA
and KIT, both encoding class III receptor tyrosine kinases involved in
cell survival, migration, and proliferation, are located adjacently on
chromosome band 4q12 [33,43]. Only base level somatic mutations
in KIT, not PDGFRA, have so far been identified in TGCT [25]. In
our study, the two somatic non-synonymous mutations in PDGFRA
were identified in exons 21 and 22, encoding the end fragment of the
intracellular tyrosine kinase and the fragment next to the carboxy-
terminal part, respectively [44]. PDGFRA has been identified as a
cancer driver in several cancer diseases with no particular mutational
hotspot region [6]. Even though our in silico analysis by Mutation
Assessor did not add functional support, we cannot rule out mutated
PDGFRA as a possible driver of TGCT pathogenesis.
Non-synonymous mutations in SUPT6H were identified in two
different tumors from the exome-sequencing series. SUPT6H is
known as a regulator of RNA polymerase II transcriptional
elongation, chromatin structure, estrogen receptor activity, and
cellular differentiation [45]. Of the present somatic non-synony-
mously mutated genes identified in this study, a significant
association between deletion and down-regulation in TGCT has
formerly been revealed in, e.g., PBX4 and WHSC1 [40,46]. PBX4
has been annotated as a homeodomain protein and is found highly
expressed in mouse testis during the first meiotic prophase of
spermatocytes [47].WHSC1 has been reported as a significant cancer
gene, linked to multiple myeloma through chromosomal transloca-
tion and found expressed during embryogenesis, although mainly in
adult testis and thymus [48].
According to the primary aim of this study, we used a high sensitivity
mutation calling algorithm, MuTect, to identify any potential
mutations identical among pairs of bilateral TGCTs [19,49,50], also
those occurring with low allele frequencies. Thus, false positive
mutations were inevitably disclosed using this strategy. However, the
high sensitivity approach underscores our conclusion of a remarkably
low mutation rate in TGCT. To determine whether mutated loci were
adequately covered, the listed mutations were dichotomized according
to the default coverage sufficiency threshold in the MuTect algorithm
(Supplementary Tables S2A and S2B) [19]. Thus, the significance of
less covered mutations should be interpreted with caution.
Bilateral TGCT and sporadic, unilateral TGCT have been found
to have similar genome profiles, suggesting that unilateral and
bilateral TGCTs develop through alterations of common cellular
pathways [51–53]. Thus, we anticipate that the mutations identified
in our study are also relevant to the pathogenesis of unilateral TGCT.In conclusion, we find evidence for independent development of
the two TGCTs in patients with bilateral disease. We further rank
TGCT as the least mutated tumor type among all adult solid
malignancies sequenced to date. Finally, we provide novel insights
into the genomic landscape of TGCT and unravel potentially
targetable oncogenes of TGCT pathogenesis, such as mutated
PDGFRA.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2014.12.005.
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